FIM
ABBV icon

Frontier Investment Management’s AbbVie ABBV Stock Holding History

Frontier Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2.05M Buy
20,917
+934
+5% +$82.2K 0.13% 72
2020
Q1 		$1.52M Buy
19,983
+10,058
+101% +$857K 0.12% 71
2019
Q4 		$879K Buy
9,925
+350
+4% +$29.1K 0.05% 125
2019
Q3 		$725K Buy
9,575
+388
+4% +$26.6K 0.05% 130
2019
Q2 		$668K Buy
9,187
+935
+11% +$73.5K 0.04% 132
2019
Q1 		$665K Buy
8,252
+486
+6% +$39.8K 0.04% 147
2018
Q4 		$716K Buy
7,766
+268
+4% +$23.6K 0.05% 137
2018
Q3 		$709K Sell
7,498
-40
-0.5% -$3.79K 0.05% 152
2018
Q2 		$698K Hold
7,538
– – 0.05% 141
2018
Q1 		$713K Sell
7,538
-1,271
-14% -$140K 0.06% 130
2017
Q4 		$852K Sell
8,809
-343
-4% -$32.3K 0.07% 124
2017
Q3 		$813K Sell
9,152
-827
-8% -$63K 0.07% 127
2017
Q2 		$724K Buy
9,979
+2,574
+35% +$173K 0.07% 132
2017
Q1 		$474K Sell
7,405
-1,036
-12% -$65.1K 0.05% 130
2016
Q4 		$529K Sell
8,441
-270
-3% -$16.5K 0.05% 138
2016
Q3 		$5.49M Buy
8,711
+1,454
+20% +$94.1K 0.05% 133
2016
Q2 		$431K Buy
7,257
+303
+4% +$18.5K 0.05% 139
2016
Q1 		$397K Sell
6,954
-48
-0.7% -$2.67K 0.05% 130
2015
Q4 		$411K Sell
7,002
-2,554
-27% -$147K 0.06% 116
2015
Q3 		$520K Sell
9,556
-2,000
-17% -$130K 0.09% 115
2015
Q2 		$776K Sell
11,556
-207
-2% -$13.5K 0.09% 110
2015
Q1 		$761K Buy
11,763
+5,280
+81% +$319K 0.11% 109
2014
Q4 		$407K Sell
6,483
-2,613
-29% -$165K 0.07% 118
2014
Q3 		$429K Buy
9,096
+2,881
+46% +$160K 0.07% 121
2014
Q2 		$351K Sell
6,215
-600
-9% -$31.5K 0.06% 121
2014
Q1 		$350K Sell
6,815
-65
-0.9% -$3.29K 0.06% 113
2013
Q4 		$360K Buy
6,880
+665
+11% +$32.7K 0.07% 109
2013
Q3 		$278K Buy
+6,215
New +$275K 0.05% 121

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Frontier Investment Management's ABBV Position: Q2 2020 in Review

Frontier Investment Management increased its AbbVie (ABBV) stake by 4.7% in Q2 2020, buying an estimated $82.2K and bringing the position to 20,917 shares worth $2.05M. The position accounts for 0.13% of the portfolio, ranked #72.

Frontier Investment Management first reported a position in ABBV in Q3 2013 and has held it in 28 quarters since. The position peaked at $5.49M in Q3 2016. 2,411 funds tracked by Wall St. Rank hold ABBV as of Q2 2020.

  • Frontier Investment Management held 20,917 shares of AbbVie worth $2.05M as of Q2 2020.
  • Frontier Investment Management bought 934 AbbVie shares in Q2 2020, an estimated $82.2K.
  • AbbVie made up 0.13% of Frontier Investment Management's portfolio in Q2 2020, its #72 holding.
  • Frontier Investment Management first reported a position in AbbVie in Q3 2013 and has held it in 28 quarters since.
  • Frontier Investment Management's AbbVie position peaked at $5.49M in Q3 2016.
  • 2,411 funds tracked by Wall St. Rank held AbbVie as of Q2 2020.

Based on Frontier Investment Management's 13F filing for Q2 2020, filed 11 Aug 2020.